Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features

Martin J. Van den Bent, Leendert H J Looijenga, K. Langenberg, Winand Dinjens, Wilfried Graveland, Ludo Uytdewilligen, Peter A. Sillevis Smitt, Robert Brian Jenkins, Johan M. Kros

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

BACKGROUND. Patients who have oligodendrogliomas (OD) that demonstrate loss of both 1p and 19q appear to have a better prognosis after they receive chemotherapy and radiotherapy compared with patients who have OD without these characteristics. It is unclear whether this improvement in outcome is due only to a better response to treatment. The authors investigated the correlation between genetic and clinical characteristics of OD in 33 patients who received chemotherapy with procarbazine, lomustine, and vincristine for recurrent disease after receiving radiotherapy. METHODS. The initial presentation, prior treatments, overall survival, and response to chemotherapy were assessed. The 1p and 19q status in OD lesions was determined with fluorescence in situ hybridization on paraffin embedded, archival material using locus specific probes. P53 mutations were assessed by polymerase chain reaction-single-strand conformation polymorphism analysis and immunohistochemistry for P53; the proliferation index was assessed with the MIB-1 antibody. RESULTS. Patients who had OD lesions with a combined loss of 1p and 19q typically presented with low-grade tumors that manifested with seizures of long-standing duration. In contrast, patients who had OD lesions without a combined loss of 1p and 19q usually presented with focal deficits that required immediate treatment. Both the response rate to chemotherapy and the time to disease progression after chemotherapy were significantly better in patients who had a combined loss of 1p and 19. Tumors with classic OD morphology more often had a combined loss of 1p and 19q, although the genotype was better at identifying patients with chemoresponsive tumors. P53 mutations were observed in three tumors, none of which had a combined loss of 1p and 19q. CONCLUSIONS. OD lesions with combined a loss of 1p and 19q have a more indolent nature compared with OD lesions that do not have these losses. Virtually all patients with these tumors present with low-grade tumors accompanied by seizures and remain stable for prolonged periods. Future trials must keep these tumor types apart.

Original languageEnglish (US)
Pages (from-to)1276-1284
Number of pages9
JournalCancer
Volume97
Issue number5
DOIs
StatePublished - Mar 1 2003

Fingerprint

Oligodendroglioma
Neoplasms
Drug Therapy
Seizures
Radiotherapy
Lomustine
Procarbazine
Mutation
Vincristine
Fluorescence In Situ Hybridization
Paraffin
Disease Progression
Therapeutics
Immunohistochemistry
Genotype
Polymerase Chain Reaction

Keywords

  • 19q
  • 1p
  • Chemotherapy
  • Low grade glioma
  • Oligoastrocytoma
  • Oligodendroglioma
  • Prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Van den Bent, M. J., Looijenga, L. H. J., Langenberg, K., Dinjens, W., Graveland, W., Uytdewilligen, L., ... Kros, J. M. (2003). Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer, 97(5), 1276-1284. https://doi.org/10.1002/cncr.11187

Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. / Van den Bent, Martin J.; Looijenga, Leendert H J; Langenberg, K.; Dinjens, Winand; Graveland, Wilfried; Uytdewilligen, Ludo; Sillevis Smitt, Peter A.; Jenkins, Robert Brian; Kros, Johan M.

In: Cancer, Vol. 97, No. 5, 01.03.2003, p. 1276-1284.

Research output: Contribution to journalArticle

Van den Bent, MJ, Looijenga, LHJ, Langenberg, K, Dinjens, W, Graveland, W, Uytdewilligen, L, Sillevis Smitt, PA, Jenkins, RB & Kros, JM 2003, 'Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features', Cancer, vol. 97, no. 5, pp. 1276-1284. https://doi.org/10.1002/cncr.11187
Van den Bent MJ, Looijenga LHJ, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer. 2003 Mar 1;97(5):1276-1284. https://doi.org/10.1002/cncr.11187
Van den Bent, Martin J. ; Looijenga, Leendert H J ; Langenberg, K. ; Dinjens, Winand ; Graveland, Wilfried ; Uytdewilligen, Ludo ; Sillevis Smitt, Peter A. ; Jenkins, Robert Brian ; Kros, Johan M. / Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. In: Cancer. 2003 ; Vol. 97, No. 5. pp. 1276-1284.
@article{c7a5a56ebd4845c2bd0191f7cadc50aa,
title = "Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features",
abstract = "BACKGROUND. Patients who have oligodendrogliomas (OD) that demonstrate loss of both 1p and 19q appear to have a better prognosis after they receive chemotherapy and radiotherapy compared with patients who have OD without these characteristics. It is unclear whether this improvement in outcome is due only to a better response to treatment. The authors investigated the correlation between genetic and clinical characteristics of OD in 33 patients who received chemotherapy with procarbazine, lomustine, and vincristine for recurrent disease after receiving radiotherapy. METHODS. The initial presentation, prior treatments, overall survival, and response to chemotherapy were assessed. The 1p and 19q status in OD lesions was determined with fluorescence in situ hybridization on paraffin embedded, archival material using locus specific probes. P53 mutations were assessed by polymerase chain reaction-single-strand conformation polymorphism analysis and immunohistochemistry for P53; the proliferation index was assessed with the MIB-1 antibody. RESULTS. Patients who had OD lesions with a combined loss of 1p and 19q typically presented with low-grade tumors that manifested with seizures of long-standing duration. In contrast, patients who had OD lesions without a combined loss of 1p and 19q usually presented with focal deficits that required immediate treatment. Both the response rate to chemotherapy and the time to disease progression after chemotherapy were significantly better in patients who had a combined loss of 1p and 19. Tumors with classic OD morphology more often had a combined loss of 1p and 19q, although the genotype was better at identifying patients with chemoresponsive tumors. P53 mutations were observed in three tumors, none of which had a combined loss of 1p and 19q. CONCLUSIONS. OD lesions with combined a loss of 1p and 19q have a more indolent nature compared with OD lesions that do not have these losses. Virtually all patients with these tumors present with low-grade tumors accompanied by seizures and remain stable for prolonged periods. Future trials must keep these tumor types apart.",
keywords = "19q, 1p, Chemotherapy, Low grade glioma, Oligoastrocytoma, Oligodendroglioma, Prognosis",
author = "{Van den Bent}, {Martin J.} and Looijenga, {Leendert H J} and K. Langenberg and Winand Dinjens and Wilfried Graveland and Ludo Uytdewilligen and {Sillevis Smitt}, {Peter A.} and Jenkins, {Robert Brian} and Kros, {Johan M.}",
year = "2003",
month = "3",
day = "1",
doi = "10.1002/cncr.11187",
language = "English (US)",
volume = "97",
pages = "1276--1284",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features

AU - Van den Bent, Martin J.

AU - Looijenga, Leendert H J

AU - Langenberg, K.

AU - Dinjens, Winand

AU - Graveland, Wilfried

AU - Uytdewilligen, Ludo

AU - Sillevis Smitt, Peter A.

AU - Jenkins, Robert Brian

AU - Kros, Johan M.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - BACKGROUND. Patients who have oligodendrogliomas (OD) that demonstrate loss of both 1p and 19q appear to have a better prognosis after they receive chemotherapy and radiotherapy compared with patients who have OD without these characteristics. It is unclear whether this improvement in outcome is due only to a better response to treatment. The authors investigated the correlation between genetic and clinical characteristics of OD in 33 patients who received chemotherapy with procarbazine, lomustine, and vincristine for recurrent disease after receiving radiotherapy. METHODS. The initial presentation, prior treatments, overall survival, and response to chemotherapy were assessed. The 1p and 19q status in OD lesions was determined with fluorescence in situ hybridization on paraffin embedded, archival material using locus specific probes. P53 mutations were assessed by polymerase chain reaction-single-strand conformation polymorphism analysis and immunohistochemistry for P53; the proliferation index was assessed with the MIB-1 antibody. RESULTS. Patients who had OD lesions with a combined loss of 1p and 19q typically presented with low-grade tumors that manifested with seizures of long-standing duration. In contrast, patients who had OD lesions without a combined loss of 1p and 19q usually presented with focal deficits that required immediate treatment. Both the response rate to chemotherapy and the time to disease progression after chemotherapy were significantly better in patients who had a combined loss of 1p and 19. Tumors with classic OD morphology more often had a combined loss of 1p and 19q, although the genotype was better at identifying patients with chemoresponsive tumors. P53 mutations were observed in three tumors, none of which had a combined loss of 1p and 19q. CONCLUSIONS. OD lesions with combined a loss of 1p and 19q have a more indolent nature compared with OD lesions that do not have these losses. Virtually all patients with these tumors present with low-grade tumors accompanied by seizures and remain stable for prolonged periods. Future trials must keep these tumor types apart.

AB - BACKGROUND. Patients who have oligodendrogliomas (OD) that demonstrate loss of both 1p and 19q appear to have a better prognosis after they receive chemotherapy and radiotherapy compared with patients who have OD without these characteristics. It is unclear whether this improvement in outcome is due only to a better response to treatment. The authors investigated the correlation between genetic and clinical characteristics of OD in 33 patients who received chemotherapy with procarbazine, lomustine, and vincristine for recurrent disease after receiving radiotherapy. METHODS. The initial presentation, prior treatments, overall survival, and response to chemotherapy were assessed. The 1p and 19q status in OD lesions was determined with fluorescence in situ hybridization on paraffin embedded, archival material using locus specific probes. P53 mutations were assessed by polymerase chain reaction-single-strand conformation polymorphism analysis and immunohistochemistry for P53; the proliferation index was assessed with the MIB-1 antibody. RESULTS. Patients who had OD lesions with a combined loss of 1p and 19q typically presented with low-grade tumors that manifested with seizures of long-standing duration. In contrast, patients who had OD lesions without a combined loss of 1p and 19q usually presented with focal deficits that required immediate treatment. Both the response rate to chemotherapy and the time to disease progression after chemotherapy were significantly better in patients who had a combined loss of 1p and 19. Tumors with classic OD morphology more often had a combined loss of 1p and 19q, although the genotype was better at identifying patients with chemoresponsive tumors. P53 mutations were observed in three tumors, none of which had a combined loss of 1p and 19q. CONCLUSIONS. OD lesions with combined a loss of 1p and 19q have a more indolent nature compared with OD lesions that do not have these losses. Virtually all patients with these tumors present with low-grade tumors accompanied by seizures and remain stable for prolonged periods. Future trials must keep these tumor types apart.

KW - 19q

KW - 1p

KW - Chemotherapy

KW - Low grade glioma

KW - Oligoastrocytoma

KW - Oligodendroglioma

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=0344863443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344863443&partnerID=8YFLogxK

U2 - 10.1002/cncr.11187

DO - 10.1002/cncr.11187

M3 - Article

VL - 97

SP - 1276

EP - 1284

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -